FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology. What is presented is a composition of an antibody for treating HER2-positive cancer containing an active antibody presented by an antibody characterised by the fact that it has a variable light and heavy chain domain, and its acidic variants, namely: glycosilated, deaminated variants, as well as a variant with a reduced disulphide bond, a syalylated variant and a irreducible variant. A number of acidic variants makes less than approximately 25%. There are described a pharmaceutical composition containing this composition, for treating HER2-positive cancer and a method for preparing the composition involving the evaluation of the acidic variants and verification of the fact that their number makes at least than approximately 25%.
EFFECT: using the invention provides the new composition, wherein the antibody and its acidic variants have the pharmacokinetic parameters that can find application in treating HER2-positive cancer.
14 cl, 17 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION OF HER2 ANTIBODIES | 2005 |
|
RU2361880C2 |
| INTRODUCTION OF FIXED DOSES OF HER-ANTIBODIES | 2005 |
|
RU2438705C2 |
| THERAPY OF MALIGNANT TUMOR, RESISTANT TO PLATINUM-BASED MEDICATIONS | 2005 |
|
RU2403065C2 |
| COMPOSITIONS OF ANTIBODIES | 2005 |
|
RU2426554C2 |
| VERSIONS OF PERTUZUMAB AND THEIR ANALYTICAL CHARACTERISTICS | 2014 |
|
RU2737727C2 |
| ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
| ANTI-HER2 ANTIBODY DRUGS FOR SUBCUTANEOUS INJECTION | 2018 |
|
RU2750821C2 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
| MULTISPECIFIC ANTIBODIES, THEREOF ANALOGUES, COMPOSITIONS AND METHODS | 2010 |
|
RU2580038C2 |
| BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS AND VARIANTS OF THEIR APPLICATION | 2018 |
|
RU2805648C2 |
